Foghorn Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Foghorn Therapeutics
FHTX Stock  USD 6.02  0.26  4.14%   
Foghorn Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Foghorn Therapeutics' valuation are provided below:
Gross Profit
-59.4 M
Profit Margin
(2.94)
Market Capitalization
352.7 M
Enterprise Value Revenue
8.571
Revenue
24.5 M
We have found one hundred twenty available fundamental signals for Foghorn Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Foghorn Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 536.5 M in 2026. Enterprise Value is likely to rise to about 514.6 M in 2026

Foghorn Therapeutics Total Revenue

27.29 Million

Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 14.4 M, Interest Income of 14.4 M or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 12.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Foghorn Stock
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Foghorn Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets285.3 M326.6 M163.1 M
Slightly volatile
Short and Long Term Debt Total46.8 M42.7 M26.1 M
Slightly volatile
Other Current Liabilities8.1 M9.8 M4.8 M
Slightly volatile
Total Current Liabilities41.5 M77 M24.1 M
Slightly volatile
Other Liabilities176 M349.6 M105.3 M
Slightly volatile
Property Plant And Equipment Net39.1 M37.5 M20.1 M
Slightly volatile
Accounts Payable4.5 M4.4 M3.1 M
Slightly volatile
Cash68.7 M63.8 M52.3 M
Slightly volatile
Non Current Assets Total41.9 M39.5 M21.7 M
Slightly volatile
Non Currrent Assets Other2.8 M2 M1.6 M
Slightly volatile
Other Assets1.091.151 M
Pretty Stable
Long Term Debt13.8 M22.6 M12.3 M
Slightly volatile
Cash And Short Term Investments191.5 M280.3 M118.3 M
Slightly volatile
Common Stock Shares Outstanding42.3 M63.1 M31.3 M
Slightly volatile
Liabilities And Stockholders Equity285.3 M326.6 M163.1 M
Slightly volatile
Non Current Liabilities Total244.8 M301.9 M160.9 M
Slightly volatile
Other Current Assets4.7 M6.7 M2.6 M
Slightly volatile
Other Stockholder Equity308.9 M589.4 M170.5 M
Slightly volatile
Total Liabilities286.4 M378.9 M185.1 M
Slightly volatile
Property Plant And Equipment Gross38.9 M54.8 M21 M
Slightly volatile
Total Current Assets243.4 M287 M141.3 M
Slightly volatile
Net Working Capital201.8 M210 M117.2 M
Slightly volatile
Common Stock3.8 K6.9 K2.5 K
Slightly volatile
Property Plant Equipment38.2 M56.8 M22.6 M
Slightly volatile
Current Deferred Revenue26.9 M52.4 M15 M
Slightly volatile
Short and Long Term Debt3.3 M3.7 M4.1 M
Slightly volatile
Short Term Debt7.3 M10.4 M6.3 M
Slightly volatile
Net Receivables2.6 M2.7 M18.9 M
Pretty Stable
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Short Term Investments172 M216.5 M123.5 M
Slightly volatile
Capital Surpluse384.1 M433.8 M335.9 M
Slightly volatile
Non Current Liabilities Other24.8 K26.1 K109.1 K
Slightly volatile

Foghorn Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income14.4 M13.7 M3.6 M
Slightly volatile
Depreciation And Amortization2.6 M3.6 M1.5 M
Slightly volatile
Interest Expense14 M13.3 M4 M
Slightly volatile
Selling General Administrative21.4 M32.6 M13.4 M
Slightly volatile
Other Operating Expenses102.4 M144.1 M65.1 M
Slightly volatile
Research Development80.7 M108.7 M51.3 M
Slightly volatile
Cost Of Revenue3.4 M3.6 M11.2 M
Slightly volatile
Total Operating Expenses93.1 M144.1 M61.1 M
Slightly volatile
Reconciled Depreciation2.4 M3.6 M1.4 M
Slightly volatile
Non Operating Income Net Other10 M9.5 M3.1 M
Slightly volatile
Selling And Marketing Expenses4.2 M4.7 M5.1 M
Slightly volatile

Foghorn Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.8 M13.7 M5 M
Slightly volatile
Begin Period Cash Flow63.2 M94.4 M39.1 M
Slightly volatile
Other Cashflows From Financing Activities1.7 M1.8 M28.4 M
Slightly volatile
Depreciation3.2 M3.6 M1.8 M
Slightly volatile
Other Non Cash Items4.6 M4 M2.3 M
Slightly volatile
Capital Expenditures774.6 K815.4 K2.3 M
Very volatile
Total Cash From Financing Activities48.5 M94.9 M57.8 M
Very volatile
End Period Cash Flow70.2 M65.7 M53.4 M
Slightly volatile
Change To Netincome17.3 M16.5 M6.2 M
Slightly volatile
Change To Liabilities5.1 M3.5 M2.8 M
Slightly volatile
Sale Purchase Of Stock1.5 M1.6 M82.9 M
Slightly volatile
Cash Flows Other Operating341.8 M325.5 M110.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.5313.181.2 K
Slightly volatile
Days Sales Outstanding66.4 K74.7 K81.6 K
Slightly volatile
Stock Based Compensation To Revenue0.570.614.9857
Slightly volatile
Capex To Depreciation0.320.333.0977
Slightly volatile
EV To Sales11.6412.251.1 K
Slightly volatile
Payables Turnover14.8214.126.4454
Slightly volatile
Sales General And Administrative To Revenue1.371.4418.2808
Slightly volatile
Research And Ddevelopement To Revenue4.574.8191.7409
Slightly volatile
Capex To Revenue0.04380.046124.5132
Slightly volatile
Cash Per Share3.424.03.1592
Slightly volatile
Days Payables Outstanding25.4326.761.1 K
Slightly volatile
Current Ratio7.354.288.932
Slightly volatile
Receivables Turnover0.00350.0040.0043
Slightly volatile
Capex Per Share0.0180.0190.0808
Pretty Stable
Revenue Per Share0.280.370.1472
Slightly volatile
Interest Debt Per Share0.880.610.7184
Slightly volatile
Debt To Assets0.280.150.2054
Pretty Stable
Operating Cycle66.4 K74.7 K81.6 K
Slightly volatile
Days Of Payables Outstanding25.4326.761.1 K
Slightly volatile
Ebt Per Ebit1.050.970.9868
Slightly volatile
Quick Ratio7.354.288.932
Slightly volatile
Net Income Per E B T0.830.941.0261
Slightly volatile
Cash Ratio0.90.956.9005
Slightly volatile
Days Of Sales Outstanding66.4 K74.7 K81.6 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.161.0941
Pretty Stable
Fixed Asset Turnover0.660.620.1916
Slightly volatile
Debt Ratio0.280.150.2054
Pretty Stable
Price Sales Ratio12.5313.181.2 K
Slightly volatile
Asset Turnover0.04020.07160.0223
Slightly volatile

Foghorn Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap536.5 M298 M417.3 M
Pretty Stable
Enterprise Value514.6 M276.9 M391 M
Pretty Stable

Foghorn Fundamental Market Drivers

Foghorn Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue52.4 M26.9 M
Total Revenue26 M27.3 M
Cost Of Revenue3.6 M3.4 M
Stock Based Compensation To Revenue 0.61  0.57 
Sales General And Administrative To Revenue 1.44  1.37 
Research And Ddevelopement To Revenue 4.81  4.57 
Capex To Revenue 0.05  0.04 
Revenue Per Share 0.37  0.28 
Ebit Per Revenue(4.09)(4.29)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY